Is Retatrutide Available in Australia? Approval Status Update
Retatrutide is not approved in Australia. Here is where Lilly's filings stand as of October 2026, how the TGA approval pathway works, and the realistic timeline before it could reach Australian pharmacies.
The short answer
No. As of October 2026, retatrutide is not approved by the Therapeutic Goods Administration (TGA) and there is no retatrutide product on the Australian Register of Therapeutic Goods (ARTG). It is not approved in the United States either. Outside clinical trials, the only retatrutide in circulation is research-grade peptide sold for laboratory use.
- TGA status
- Not approved
- FDA status
- Not approved
- FDA filing
- Planned Q1 2027
- Earliest AU estimate
- 2028 or later
Where Lilly's applications stand
- Clinical trials: Lilly has reported results from several phase 3 TRIUMPH trials through 2026. Its cardiovascular and kidney outcomes trial is still running, with an estimated primary completion in 2029.
- FDA filing: In its second-quarter 2026 results, Lilly said the clinical data package was complete and that it planned to submit to the FDA in the first quarter of 2027.
- Review time: FDA reviews commonly take around 10 to 12 months, so a US decision would most likely land in late 2027 or 2028. That is an estimate, not a Lilly commitment.
- Aug 2026Lilly says the data package is complete.
- Q1 2027Planned FDA submission.
- Late 2027 to 2028Likely FDA decision window, if the filing goes ahead as planned.
- 2028 or laterEarliest realistic Australian approval, depending on when Lilly files with the TGA.
How a medicine reaches Australia
Australian approval needs its own application to the TGA. There are two broad routes:
| Pathway | How it works | Typical effect on timing |
|---|---|---|
| Standard evaluation | The TGA reviews the full data package itself. | Longest route |
| Comparable overseas regulator (COR) | The TGA can rely partly on an assessment already completed by a trusted overseas regulator such as the FDA. | Can shorten the review once an overseas approval exists |
Lilly has not announced an Australian timeline. On the information public today, a prescription retatrutide product in Australia looks unlikely before 2028.
When will retatrutide be available in Australia?
The honest answer is: not before the US decision, and probably some months after it. The order of events to watch for is an FDA filing, an FDA decision, then a TGA application and decision. We will update this page as each step happens.
Retatrutide: how to get it today
There are two routes, and they serve completely different purposes:
| Route | Who it is for | What you receive |
|---|---|---|
| Clinical trials and expanded access | Trial participants, through trial sites | Investigational medicine under medical supervision |
| Research-grade peptide | Laboratories and researchers | Lyophilised retatrutide for research use only |
Research-grade retatrutide is not a medicine and is not for human consumption. If you are sourcing it for laboratory work, read what retatrutide is and how to check a COA first.
Sources
- Eli Lilly Q2 2026 results (SEC filing)
- Drugs.com: retatrutide approval status
- ClinicalTrials.gov: TRIUMPH-Outcomes
Further reading
For laboratory research use only. Not for human consumption. Not medical or legal advice.
